| CEO Name | Hubertus von Baumbach |
| Nationality | Germany |
| Net Worth Estimation | $1.5 billion |
Hubertus von Baumbach is part of the founding Boehringer and von Baumbach families, who collectively control all shares of Boehringer Ingelheim GmbH, one of the world's largest privately held pharmaceutical companies. His estimated net worth of around $1.5 billion USD primarily stems from his inherited ownership stake, reflecting the company's multibillion-dollar annual revenues and longstanding family wealth.
Hubertus von Baumbach's estimated net worth of $1,500,000,000 is 200% to 15,000% higher than the typical pharmaceutical CEO range of $10,000,000 to $500,000,000. This positions him significantly above his industry peers in terms of estimated wealth.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Hubertus von Baumbach Performance in Boehringer Ingelheim GmbH
Hubertus von Baumbach, CEO of Boehringer Ingelheim GmbH, demonstrates strategic leadership with a strong focus on innovation and sustainable growth. His decision-making emphasizes long-term investment in research and development, driving advancements in pharmaceuticals and animal health. Under his leadership, the company has enhanced global market presence and improved financial performance, solidifying its status as a leading healthcare enterprise.
Latest News
Boehringer Ingelheim Expands Autoimmune Pipeline with Global Licensing Deal for CDR111.
Boehringer Ingelheim and CDR-Life announced a new global licensing agreement to develop CDR111, a trispecific T-cell engager targeting autoimmune diseases, with potential payments up to $570 million, including $48 million upfront. The partnership aims to address conditions like lupus and multiple sclerosis by resetting immune dysregulation through B-cell depletion.
Source: http://www.globenewswire.com/news-release/2025/11/04/3180237/0/en/Boehringer-Ingelheim-and-CDR-Life-Expand-Collaboration-Efforts-with-Global-Licensing-Agreement-for-CDR111-an-Antibody-Based-Trispecific-M-gager-for-Autoimmune-Diseases.html